Drugs that interfere with the immune mechanism responsible for thrombus formation in APS, starting from the binding of antibodies to their target antigen β2GPI and proceeding with complement activation, represent an alternative therapeutic strategy. Here, APOH is linked to autoimmune polyendocrinopathy.